Bystolic ‘Side Deals’ Deemed Legit, Not Generic Delay Plans

In the Media
1 min read

White & Case is mentioned in Law360 for securing a dismissal with prejudice of all claims brought by direct and indirect purchasers in class-action and opt-out complaints against AbbVie and other pharmaceutical firms.

White & Case partner Eric Grannon presented oral argument on the motion in November 2022 on behalf of all Defendants. Plaintiffs had alleged that Defendants conspired to delay competition for generic forms of hypertension drug Bystolic by entering into reverse payment agreements under FTC v. Actavis.

The White & Case team representing AbbVie was led by Mark Gidley, Eric Grannon, Peter Carney, Adam Acosta, Celia McLaughlin, Holly Letourneau and Kelly Newman.

See the full Law360 article here.

Press contact
For more information please speak to your local media contact.